It’s been a pretty miserable year for biotech’s biggest names, rife with disappointments and sluggish share-price performance. Not so for two middlewights of the industry: Vertex Pharmaceuticals Inc. and Alexion Pharmaceuticals Inc.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,